PRL and peripartum cardiomyopathy: The accumulation of knowledge about the functions and effects of the PRL/vasoinhibin axis from basic studies has reached a critical mass which has triggered translation from bench to bedside and back, at present culminating in two clinical studies in which the PRL/vasoinhibin axis is target of therapeutic interventions to treat diabetic retinal diseases and peripartum cardiomyopathy (PPCM).